# US 2020/0370023 A1 · Novel and efficient method for reprogramming blood to induced pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0370023 A1
- Document ID: US20200370023A1
- Status: Published application
- Kind: A1
- Application number: 16/919,456
- Filed: 2020-07-02
- Published: 2020-11-26
- Earliest claimed: 2016-06-16
- Assignees: Cedars-Sinai Medical Center
- Applicants: Cedars-Sinai Medical Center
- Inventors: Dhruv Sareen; Loren A. Ornelas; Clive Svendsen
- Web page: https://patentgrep.com/patent/US20200370023A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2500/25: Insulin-transferrin; Insulin-transferrin-selenium
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/60: Transcription factors
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2501/608: Lin28
- C12N 2502/02: embryonic cells
- C12N 2506/11: from blood or immune system cells
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.

## Claims

### Claim 1

A method of generating blood cell derived induced pluripotent stem cells, comprising:
providing a quantity of blood cells;
delivering a quantity of EBNA1 and reprogramming factors into the blood cells; and
culturing the blood cells in a reprogramming media for at least 4 days, wherein delivering the EBNA1 and reprogramming factors, and culturing in a reprogramming media generates blood cell derived induced pluripotent stem cells, wherein the reprogramming factors are encoded in one or more oriP/EBNA1 derived vectors.

### Claim 2 (depends on 1)

The method of claim 1, wherein delivering a quantity of reprogramming factors comprises nucleofection.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reprogramming factors comprise one or more factors selected from the group consisting of: Oct-4, Sox-2, Klf-4, c-Myc, Lin-28, SV40 Large T Antigen (“SV40LT”), and short hairpin RNAs targeting p53 (“shRNA-p53”).

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein the one or more oriP/EBNA1 derived vectors comprise pEP4 E02S ET2K, pCXLE-hOCT3/4-shp53-F, pCXLE-hSK, pCXLE-hUL, and pCWB-EBNA1.

### Claim 6 (depends on 1)

The method of claim 1, comprising plating of the blood cells on a treated cell culture surface after delivering reprogramming factors into the blood cells, and culturing the blood cells in a reprogramming media on said treated cell culture surface.

### Claim 7 (depends on 6)

The method of claim 6, wherein the treated cell culture surface comprises plating of mouse embryonic feeders (MEFs).

### Claim 8 (depends on 6)

The method of claim 6, wherein the treated cell culture surface comprises an extracellular matrix protein.

### Claim 9 (depends on 8)

The method of claim 8, wherein the extracellular matrix protein comprises laminin.

### Claim 10 (depends on 9)

The method of claim 9, wherein laminin comprises L-521.

### Claim 11 (depends on 1)

The method of claim 1, wherein the reprogramming media comprises embryonic stem cell (ESC) media.

### Claim 12 (depends on 11)

The method of claim 11, wherein the ESC media comprises basic fibroblast growth factor (bFGF).

### Claim 13 (depends on 1)

The method of claim 1, wherein the reprogramming media comprises E7 media.

### Claim 14 (depends on 13)

The method of claim 13, wherein the reprogramming media comprises E7 media comprising L-Ascorbic Acid, Transferrin, Sodium Bicarbonate, Insulin, Sodium Selenite and/or bFGF.

### Claim 15 (depends on 1)

The method of claim 1, wherein culturing the blood cells in a reprogramming media is for at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 days.

### Claim 16 (depends on 1)

The method of claim 1, wherein culturing the blood cells in a reprogramming media is for at least 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 days.

### Claim 17 (depends on 1)

A cell line comprising blood cell derived induced pluripotent stem cells generated by the method of claim 1.

### Claim 18 (depends on 1)

The method of claim 1, wherein the blood cells are isolated from a subject possessing a disease mutation.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease mutation is associated with a neurodegenerative disease, disorder and/or condition.

### Claim 20 (depends on 18)

The method of claim 18, wherein the disease mutation is associated with an inflammatory bowel disease, disorder, and/or condition.

### Claim 21 (depends on 1)

The method of claim 1, wherein blood cells are non T-cell, non B-cell mononuclear cells.

### Claim 22 (depends on 1)

The method of claim 1, wherein the blood cells are a sample drawn from a human subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the sample is whole blood.

### Claim 24 (depends on 22)

The method of claim 22, wherein the sample is peripheral blood.

### Claim 25 (depends on 22)

The method of claim 22, wherein the sample is an isolated component of non T-cell, non B-cell mononuclear cells.

### Claim 26

A blood cell derived induced pluripotent stem cell line.
